VYNE Therapeutics (VYNE) Competitors $1.67 +0.03 (+1.83%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$1.66 0.00 (-0.30%) As of 04/3/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VYNE vs. CHRS, VXRT, OPTN, ANIX, ADVM, FATE, VOR, BDTX, OCX, and SNTIShould you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include Coherus BioSciences (CHRS), Vaxart (VXRT), OptiNose (OPTN), Anixa Biosciences (ANIX), Adverum Biotechnologies (ADVM), Fate Therapeutics (FATE), Vor Biopharma (VOR), Black Diamond Therapeutics (BDTX), OncoCyte (OCX), and Senti Biosciences (SNTI). These companies are all part of the "pharmaceutical products" industry. VYNE Therapeutics vs. Coherus BioSciences Vaxart OptiNose Anixa Biosciences Adverum Biotechnologies Fate Therapeutics Vor Biopharma Black Diamond Therapeutics OncoCyte Senti Biosciences Coherus BioSciences (NASDAQ:CHRS) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, community ranking, profitability, earnings and institutional ownership. Do analysts rate CHRS or VYNE? Coherus BioSciences currently has a consensus price target of $5.38, indicating a potential upside of 558.14%. VYNE Therapeutics has a consensus price target of $6.88, indicating a potential upside of 311.68%. Given Coherus BioSciences' higher possible upside, research analysts clearly believe Coherus BioSciences is more favorable than VYNE Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coherus BioSciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75VYNE Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor CHRS or VYNE? In the previous week, Coherus BioSciences had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 3 mentions for Coherus BioSciences and 2 mentions for VYNE Therapeutics. Coherus BioSciences' average media sentiment score of 0.00 beat VYNE Therapeutics' score of -0.14 indicating that Coherus BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral VYNE Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is CHRS or VYNE more profitable? Coherus BioSciences has a net margin of -0.15% compared to VYNE Therapeutics' net margin of -6,896.55%. Coherus BioSciences' return on equity of 0.00% beat VYNE Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coherus BioSciences-0.15% N/A -24.44% VYNE Therapeutics -6,896.55%-43.73%-38.55% Which has more risk & volatility, CHRS or VYNE? Coherus BioSciences has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Does the MarketBeat Community favor CHRS or VYNE? Coherus BioSciences received 414 more outperform votes than VYNE Therapeutics when rated by MarketBeat users. However, 67.31% of users gave VYNE Therapeutics an outperform vote while only 65.36% of users gave Coherus BioSciences an outperform vote. CompanyUnderperformOutperformCoherus BioSciencesOutperform Votes44965.36% Underperform Votes23834.64% VYNE TherapeuticsOutperform Votes3567.31% Underperform Votes1732.69% Which has preferable earnings & valuation, CHRS or VYNE? VYNE Therapeutics has lower revenue, but higher earnings than Coherus BioSciences. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoherus BioSciences$266.96M0.35-$237.89M$0.194.30VYNE Therapeutics$501K50.70-$28.45M-$0.94-1.78 Do institutionals & insiders have more ownership in CHRS or VYNE? 72.8% of Coherus BioSciences shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 7.6% of Coherus BioSciences shares are owned by insiders. Comparatively, 4.8% of VYNE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryCoherus BioSciences beats VYNE Therapeutics on 11 of the 18 factors compared between the two stocks. Remove Ads Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYNE vs. The Competition Export to ExcelMetricVYNE TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.40M$6.72B$5.53B$7.50BDividend YieldN/A2.80%4.86%4.05%P/E Ratio-1.946.9923.2318.08Price / Sales50.70198.60362.7586.83Price / CashN/A65.6738.1634.64Price / Book0.265.926.493.99Net Income-$28.45M$142.37M$3.21B$247.18M7 Day Performance-1.76%-7.24%-4.90%-4.25%1 Month Performance-27.71%-10.45%-0.07%-6.87%1 Year Performance-41.20%-14.58%6.45%-3.73% VYNE Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYNEVYNE Therapeutics2.5618 of 5 stars$1.67+1.8%$6.88+311.7%-46.1%$25.40M$501,000.00-1.9430Short Interest ↑CHRSCoherus BioSciences3.0591 of 5 stars$0.81-3.8%$5.38+566.0%-65.7%$93.53M$266.96M-10.09330Gap DownVXRTVaxart2.5077 of 5 stars$0.41-2.7%$3.00+631.7%-69.2%$93.46M$28.70M-1.00120OPTNOptiNose2.8632 of 5 stars$9.17+0.2%$9.00-1.9%-55.8%$92.25M$78.23M-2.18190Positive NewsANIXAnixa Biosciences2.9206 of 5 stars$2.86-3.7%$9.00+214.7%-20.7%$92.08M$210,000.00-7.335ADVMAdverum Biotechnologies4.3132 of 5 stars$4.37-5.2%$27.83+536.9%-70.5%$90.91M$1M-0.73190News CoveragePositive NewsGap DownFATEFate Therapeutics3.2223 of 5 stars$0.79-7.0%$5.43+587.1%-90.3%$90.54M$13.63M-0.48550Gap DownVORVor Biopharma2.2848 of 5 stars$0.72-4.4%$8.86+1,130.2%-71.9%$89.89MN/A-0.44140Gap DownBDTXBlack Diamond Therapeutics2.5505 of 5 stars$1.55-3.7%$14.60+841.9%-69.8%$87.83MN/A-1.1790Gap DownOCXOncoCyte2.5076 of 5 stars$3.06-4.7%$4.56+49.1%-0.7%$87.51M$1.88M-0.70120Short Interest ↑SNTISenti Biosciences2.8701 of 5 stars$3.36-2.0%$10.00+197.6%-12.0%$87.37M$2.56M-0.224Gap Up Remove Ads Related Companies and Tools Related Companies CHRS Competitors VXRT Competitors OPTN Competitors ANIX Competitors ADVM Competitors FATE Competitors VOR Competitors BDTX Competitors OCX Competitors SNTI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VYNE) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VYNE Stock Free VYNE Stock Alerts